Table 4 New medication prescriptions during the baseline and post-acute phasesa stratified by disposition during acute COVID-19
USC medication class description | No hospitalization (n = 3546) | Hospitalization without ICU admission (n = 164) | ICU admission (n = 82) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Baseline phase, n (%) | Post-acute phase, n (%) | Change from baseline to post-acute phase, Δ (% change) | Baseline phase, n (%) | Post-acute phase, n (%) | Change from baseline to post-acute phase, Δ (% change) | Baseline phase, n (%) | Post-acute phase, n (%) | Change from baseline to post-acute phase, Δ (% change) | |
Hormones | 214 (6.0) | 617 (17.4) | 403 (188.3) | 9 (5.5) | 27 (16.5) | 18 (200.0) | 5 (6.1) | 14 (17.1) | 9 (180.0) |
Vascular agents | 114 (3.2) | 227 (6.4) | 113 (99.1) | 9 (5.5) | 25 (15.2) | 16 (177.8) | 7 (8.5) | 25 (30.5) | 18 (257.1) |
Musculoskeletal | 140 (3.9) | 232 (6.5) | 92 (65.7) | 11 (6.7) | 12 (7.3) | 1 (9.1) | 2 (2.4) | 5 (6.1) | 3 (150.0) |
Antihyperlipidemic agents | 136 (3.8) | 208 (5.9) | 72 (52.9) | 8 (4.9) | 17 (10.4) | 9 (112.5) | 4 (4.9) | 14 (17.1) | 10 (250.0) |
Neurological/neuromuscular disorders | 110 (3.1) | 171 (4.8) | 61 (55.5) | 5 (3.0) | 10 (6.1) | 5 (100.0) | 3 (3.7) | 9 (11.0) | 6 (200.0) |
Analgesics | 274 (7.7) | 438 (12.4) | 164 (59.9) | 17 (10.4) | 29 (17.7) | 12 (70.6) | 11 (13.4) | 18 (22.0) | 7 (63.6) |
Psychotherapeutic drugs | 341 (9.6) | 520 (14.7) | 179 (52.5) | 9 (5.5) | 24 (14.6) | 15 (166.7) | 4 (4.9) | 16 (19.5) | 12 (300.0) |
Gastrointestinal | 178 (5.0) | 258 (7.3) | 80 (44.9) | 12 (7.3) | 19 (11.6) | 7 (58.3) | 1 (1.2) | 8 (9.8) | 7 (700.0) |
Ophthalmic preparations | 102 (2.9) | 143 (4.0) | 41 (40.2) | 8 (4.9) | 12 (7.3) | 4 (50.0) | 2 (2.4) | 2 (2.4) | 0 (0.0) |
Genitourinary | 161 (4.5) | 222 (6.3) | 61 (37.9) | 7 (4.3) | 6 (3.7) | –1 (–14.3) | 0 (0.0) | 7 (8.5) | 7 (NC) |
Antinauseants | 149 (4.2) | 194 (5.5) | 45 (30.2) | 10 (6.1) | 13 (7.9) | 3 (30.0) | 3 (3.7) | 6 (7.3) | 3 (100.0) |
Antiarthritics | 345 (9.7) | 452 (12.7) | 107 (31.0) | 25 (15.2) | 26 (15.9) | 1 (4.0) | 11 (13.4) | 14 (17.1) | 3 (27.3) |
Dermatologicals | 135 (3.8) | 160 (4.5) | 25 (18.5) | 2 (1.2) | 3 (1.8) | 1 (50.0) | 2 (2.4) | 8 (9.8) | 6 (300.0) |
Thyroid therapy | 103 (2.9) | 123 (3.5) | 20 (19.4) | 1 (0.6) | 3 (1.8) | 2 (200.0) | 1 (1.2) | 3 (3.7) | 2 (200.0) |
Anti-fungal agents | 197 (5.6) | 221 (6.2) | 24 (12.2) | 6 (3.7) | 8 (4.9) | 2 (33.3) | 3 (3.7) | 7 (8.5) | 4 (133.3) |
Contraceptives | 273 (7.7) | 273 (7.7) | 0 (0.0) | 3 (1.8) | 6 (3.7) | 3 (100.0) | 2 (2.4) | 2 (2.4) | 0 (0.0) |
Anti-infectives, systemic | 963 (27.2) | 867 (24.5) | –96 (–10.0) | 39 (23.8) | 43 (26.2) | 4 (10.3) | 18 (22.0) | 18 (22.0) | 0 (0.0) |
Respiratory therapy | 442 (12.5) | 328 (9.3) | –114 (–25.8) | 18 (11.0) | 25 (15.2) | 7 (38.9) | 9 (11.0) | 16 (19.5) | 7 (77.8) |
Antivirals | 280 (7.9) | 142 (4.0) | –138 (–49.3) | 2 (1.2) | 4 (2.4) | 2 (100.0) | 5 (6.1) | 1 (1.2) | –4 (–80.0) |
Cough/cold/flu preparations | 282 (8.0) | 70 (2.0) | –212 (–75.2) | 14 (8.5) | 6 (3.7) | –8 (–57.1) | 6 (7.3) | 4 (4.9) | –2 (–33.3) |